What happened with RLAY today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Relay Therapeutics is a clinical-stage drug developer working on treatments for cancer and genetic diseases. Its Dynamo platform combines computer models of how proteins move with laboratory experiments to design drug candidates. One candidate, zovegalisib, is being developed with other therapies for breast cancer with specific genetic mutations. None of its candidates is approved for sale, and it has never earned revenue from product sales.
Its revenue comes from licensing rather than selling medicines. Elevar holds worldwide rights to develop and commercialize lirafugratinib and pays Relay under that agreement, including upfront and development milestone payments. This makes licensing income dependent on Elevar’s progress with the drug; potential royalties also depend on eventual sales.
Relay has principally funded its operations by raising capital, not through revenue. It relies on outside organizations to conduct clinical trials and manufacture its candidates. Selling its own medicines would require successful trials and regulatory approval, followed by market acceptance and adequate insurance coverage and reimbursement. Continued development also depends on access to additional funding.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Relay Therapeutics’ prospects hinge on zovegalisib’s clinical success against rivals including Roche’s ITOVEBI, while its current licensing revenue depends on Elevar’s lirafugratinib agreement.
Celcuity’s gedatolisib competes with Relay’s zovegalisib by targeting the PI3K pathway in HR-positive, HER2-negative advanced breast cancer. Watch gedatolisib’s Phase 3 results in that patient group; Celcuity’s eventual drug sales would also depend on insurers and government health programs covering treatment.
Novartis sells PIQRAY for breast cancer, competing with the investigational PI3Kα inhibitor Relay is developing, and the companies also overlap in vascular-malformation treatments. PIQRAY news and Novartis’s vascular-malformation development progress are more relevant to Relay than Novartis’s overall prescription-drug sales.
AstraZeneca’s approved TRUQAP is an existing rival in the breast-cancer treatment market Relay’s zovegalisib seeks to enter, targeting the PI3K/AKT/mTOR pathway. For Relay holders, TRUQAP’s treatment results and regulatory news matter more directly than sales of AstraZeneca’s other cancer medicines.
Relay’s planned combination treatment depends partly on Pfizer’s investigational atirmociclib: the companies are testing it with zovegalisib and fulvestrant in PI3Kα-mutated, HR-positive, HER2-negative metastatic breast cancer. Pfizer mainly earns money selling medicines, but the key issue for Relay is whether atirmociclib proves safe and effective and gains approval—without that approval, Relay cannot market this combination.
Palvella Therapeutics identifies Relay as a potential rival in medicines for serious rare skin diseases and vascular malformations. Watch its development progress rather than drug sales: as of December 31, 2025, Palvella had no approved products and had never generated product revenue.
IDEAYA Biosciences offers a comparison for Relay’s ability to turn structure-informed cancer-drug research into payments from pharmaceutical partners. IDEAYA received $210 million upfront for giving Servier development and commercial rights to darovasertib outside the United States, while Relay receives upfront and milestone payments from Elevar for global rights to lirafugratinib.
Revolution Medicines and Relay both need clinical evidence that their targeted cancer drugs can effectively block proteins that drive cancer. Revolution’s trials of drugs targeting active RAS, including daraxonrasib, offer a comparison for that challenge, rather than a read-through from current collaboration income: it reported none in 2024 or 2025.
Recursion Pharmaceuticals is a comparison for whether Relay’s combination of computation and experiments can produce medicines and attract pharmaceutical partners. Recursion develops its own investigational drugs and drug pipelines for partners; clinical progress and new partnerships are the signals to watch, rather than commercial drug sales, for which it has no sales or distribution capabilities yet.
Pfizer Inc. earningsPFE
If Pfizer’s report provides an update on atirmociclib, it will show whether the investigational partner drug in Relay’s planned combination is still progressing.
Look for any update on Pfizer’s trial of atirmociclib with Relay’s zovegalisib and fulvestrant, including safety or efficacy findings. Progress would support further testing of the combination; safety, efficacy or development problems would constrain its prospects, and Relay cannot market the combination without approval of atirmociclib.
Relay Therapeutics, Inc. earningsThis company
Relay Therapeutics has no product-sales revenue and relies on financing and collaboration payments to fund research, so this report will show whether it can advance clinical programs while curbing research costs and cash use.
Read research and development expense and operating cash use alongside clinical-program progress. Lower spending and cash use with programs still advancing would suggest Relay can sustain development on less; lower spending alongside slower progress would suggest the savings may come from delaying its pipeline.
